| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Marc-Antoine Belaud-Rotureau | Q41921795 |
| P2093 | author name string | Vincent Lavoué | |
| Fabrice Foucher | |||
| Florian Cabillic | |||
| Jean Levêque | |||
| Sébastien Henno | |||
| Aurélie Thédrez | |||
| Vincent Jauffret | |||
| Veronique Catros | |||
| P2860 | cites work | Antigen-specific active immunotherapy for ovarian cancer | Q24240962 |
| B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells | Q24291070 | ||
| The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial | Q24629295 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| T helper 17 cells promote cytotoxic T cell activation in tumor immunity | Q24646584 | ||
| ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow | Q24674849 | ||
| B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma | Q24676809 | ||
| Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer | Q24685406 | ||
| Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC) | Q24804586 | ||
| Suppression, subversion and escape: the role of regulatory T cells in cancer progression | Q27026151 | ||
| Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion | Q27860475 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| Celecoxib for the prevention of colorectal adenomatous polyps | Q28200375 | ||
| Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? | Q28287583 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| Tolerogenic dendritic cells | Q29618755 | ||
| Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer | Q29620068 | ||
| A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer | Q30445914 | ||
| Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice | Q30493889 | ||
| Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity | Q33186765 | ||
| Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves | Q41952605 | ||
| Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery | Q42692798 | ||
| Advanced Ovarian Cancer: Phase III Randomized Study of Sequential Cisplatin–Topotecan and Carboplatin–Paclitaxel vs Carboplatin–Paclitaxel | Q42862031 | ||
| Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study | Q42882546 | ||
| Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity | Q43144666 | ||
| Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells | Q43648761 | ||
| Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial | Q43886638 | ||
| Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial | Q44426842 | ||
| HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group | Q44695868 | ||
| Cellular immunity in breast cancer patients completing taxane treatment | Q44909385 | ||
| Human leukocyte antigen-G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma | Q45061505 | ||
| GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. | Q46490849 | ||
| Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. | Q46616110 | ||
| Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma | Q46883280 | ||
| Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer | Q47573543 | ||
| Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). | Q47969162 | ||
| Antigen-presenting cell (APC) subsets in ovarian cancer | Q37873929 | ||
| ChemoImmunoModulation: immune regulation by the antineoplastic chemotherapeutic agents | Q37993189 | ||
| Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. | Q38047057 | ||
| Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion | Q38054472 | ||
| Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy | Q38082845 | ||
| Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer | Q38419271 | ||
| PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction | Q39206599 | ||
| Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. | Q39367745 | ||
| Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. | Q39457367 | ||
| Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion | Q39627208 | ||
| PGE2 inhibits natural killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling | Q39703888 | ||
| Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer | Q39741066 | ||
| Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma | Q39814919 | ||
| Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies | Q39828440 | ||
| Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer | Q39843619 | ||
| The concept of immunological surveillance | Q39994321 | ||
| Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer | Q40019095 | ||
| Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. | Q40031362 | ||
| Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. | Q40075206 | ||
| Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta | Q40168787 | ||
| Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells | Q40197317 | ||
| CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells | Q40259796 | ||
| Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses | Q40302572 | ||
| Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells | Q40382287 | ||
| Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells | Q40395279 | ||
| TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. | Q40657544 | ||
| Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells | Q40741896 | ||
| Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. | Q40758963 | ||
| Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. | Q41440080 | ||
| Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the HER-2/neu Proto-oncogene | Q41525509 | ||
| Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma | Q41792382 | ||
| Suppressing the suppressor: Role of immunosuppressive regulatory T cells in cancer surgery | Q37419987 | ||
| Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes | Q37424014 | ||
| Immune parameters affecting the efficacy of chemotherapeutic regimens | Q37848665 | ||
| Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer | Q80233809 | ||
| Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells | Q80274418 | ||
| TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs | Q80284232 | ||
| Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma | Q81377645 | ||
| [Prognostic significance of tumor-associated macrophage infiltration in advanced epithelial ovarian carcinoma] | Q84259532 | ||
| A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission | Q87355944 | ||
| Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity | Q33329040 | ||
| Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors | Q33488520 | ||
| Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines | Q33566336 | ||
| Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival | Q33584997 | ||
| MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells | Q33638962 | ||
| COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function | Q33678308 | ||
| Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer | Q33842859 | ||
| Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes | Q33933875 | ||
| Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study | Q34008331 | ||
| Human ovarian tumor cells escape γδ T cell recognition partly by down regulating surface expression of MICA and limiting cell cycle related molecules | Q34025938 | ||
| The basic principles of chimeric antigen receptor design | Q34036213 | ||
| Sensitization of ovarian carcinoma cells with zoledronate restores the cytotoxic capacity of Vγ9Vδ2 T cells impaired by the prostaglandin E2 immunosuppressive factor: implications for immunotherapy | Q34077388 | ||
| Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells | Q34103579 | ||
| Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma | Q34122791 | ||
| Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer | Q34122828 | ||
| Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer | Q34210036 | ||
| Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions | Q34248531 | ||
| Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer | Q34396474 | ||
| Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas | Q34405149 | ||
| Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes | Q34480058 | ||
| Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes | Q34664957 | ||
| Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy | Q34681370 | ||
| Immunotherapy for ovarian cancer: what's next? | Q34743514 | ||
| A quantitative deficiency in peripheral blood Vγ9Vδ2 cells is a negative prognostic biomarker in ovarian cancer patients. | Q34743969 | ||
| Th17 cells in cancer: help or hindrance? | Q34913808 | ||
| Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma | Q34943798 | ||
| Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments | Q34983123 | ||
| Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer | Q35032491 | ||
| All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients | Q35062106 | ||
| Immunity and immune suppression in human ovarian cancer | Q35138135 | ||
| Immunologic principles and immunotherapeutic approaches in ovarian cancer | Q35213250 | ||
| Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. | Q35237477 | ||
| Tumour macrophages as potential targets of bisphosphonates. | Q35547309 | ||
| Distinct mechanisms of immunosuppression as a consequence of major surgery | Q35549389 | ||
| ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. | Q50935651 | ||
| A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. | Q50993058 | ||
| Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. | Q51962005 | ||
| Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. | Q51989897 | ||
| A critique of surgical cytoreduction in advanced ovarian cancer. | Q52925628 | ||
| NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. | Q53257187 | ||
| Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. | Q53494978 | ||
| The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. | Q53646174 | ||
| Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. | Q53961800 | ||
| The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells | Q56902123 | ||
| Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host | Q57054792 | ||
| Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients | Q57220173 | ||
| Quantitative and Functional Alterations of Plasmacytoid Dendritic Cells Contribute to Immune Tolerance in Ovarian Cancer | Q57570998 | ||
| Soluble HLA-G molecules are increased in lymphoproliferative disorders | Q59607591 | ||
| Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss | Q61626110 | ||
| Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma | Q61626123 | ||
| Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide | Q69485236 | ||
| T-cell recognition of ovarian cancer | Q72858925 | ||
| Natural killer cell activity and progression-free survival in ovarian cancer | Q72956536 | ||
| Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta | Q73403879 | ||
| Tumor vaccine for ovarian carcinoma targeting sperm protein 17 | Q74116730 | ||
| Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines | Q74211468 | ||
| Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides | Q77738182 | ||
| Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group | Q78785334 | ||
| The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR | Q79149161 | ||
| Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125) | Q80037226 | ||
| The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function | Q80093598 | ||
| CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients | Q35588533 | ||
| Ovarian cancer progression is controlled by phenotypic changes in dendritic cells | Q35826026 | ||
| Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. | Q35835489 | ||
| Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer | Q35921697 | ||
| Functional diversity and plasticity of human dendritic cell subsets | Q36090933 | ||
| HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma | Q36184723 | ||
| Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer | Q36260673 | ||
| A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer | Q36299662 | ||
| Regulatory T cells in ovarian cancer: biology and therapeutic potential | Q36321305 | ||
| Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses | Q36376333 | ||
| Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death | Q36403093 | ||
| A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma | Q36425427 | ||
| Human Th17 cells in patients with cancer: Friends or foe? | Q36456517 | ||
| Management of platinum-sensitive recurrent ovarian cancer | Q36485320 | ||
| Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients | Q36498459 | ||
| The anticancer immune response: indispensable for therapeutic success? | Q36677608 | ||
| Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. | Q36715028 | ||
| Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells | Q36742588 | ||
| Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity | Q36821053 | ||
| Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells | Q36839509 | ||
| Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression | Q36983876 | ||
| Creating immune privilege: active local suppression that benefits friends, but protects foes. | Q37026641 | ||
| Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression | Q37035365 | ||
| The impact of T-cell immunity on ovarian cancer outcomes | Q37118142 | ||
| Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma | Q37169042 | ||
| PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment | Q37193568 | ||
| Immunogenic cancer cell death: a key-lock paradigm | Q37198125 | ||
| Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. | Q37294314 | ||
| The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans | Q37363065 | ||
| In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells | Q37369512 | ||
| Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer | Q37369523 | ||
| Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. | Q37397924 | ||
| Chemokine receptors as targets for cancer therapy | Q37411422 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immune tolerance | Q1356761 |
| glandular and epithelial neoplasm | Q5566612 | ||
| ovarian neoplasm | Q11793790 | ||
| carcinoma | Q33525 | ||
| ovarian carcinoma | Q18556145 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 147 | |
| P577 | publication date | 2013-06-13 | |
| P1433 | published in | Journal of Translational Medicine | Q15716664 |
| P1476 | title | Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer | |
| P478 | volume | 11 |
| Q53405410 | A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. |
| Q28601320 | Anti-α-enolase is a prognostic marker in postoperative lung cancer patients |
| Q36842192 | Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro |
| Q33930609 | Attenuated Listeria monocytogenes reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis. |
| Q36095328 | B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer |
| Q42362802 | CAR-T cell therapy in ovarian cancer: from the bench to the bedside |
| Q37173597 | CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer |
| Q64079831 | Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer |
| Q92524991 | Differential expression of immune related genes in high-grade ovarian serous carcinoma |
| Q49885235 | Effect of ovarian cancer ascites on SKOV-3 cells proteome: new proteins associated with aggressive phenotype in epithelial ovarian cancer |
| Q28088304 | From mice to humans: developments in cancer immunoediting |
| Q36685395 | IL-27 induces the expression of IDO and PD-L1 in human cancer cells |
| Q37224568 | Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer |
| Q64903098 | Immune reaction by cytoreductive prostatectomy. |
| Q40470696 | Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways. |
| Q35157858 | Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer. |
| Q52689050 | Myeloid-derived suppressor cells in ovarian cancer: friend or foe? |
| Q92153231 | P-MAPA and Interleukin-12 Reduce Cell Migration/Invasion and Attenuate the Toll-Like Receptor-Mediated Inflammatory Response in Ovarian Cancer SKOV-3 Cells: A Preliminary Study |
| Q48533544 | P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling |
| Q39402079 | Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer. |
| Q35798892 | Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer. |
| Q57174538 | Resident Memory-Like Tumor-Infiltrating Lymphocytes (TIL): Latest Players in the Immuno-Oncology Repertoire |
| Q90650349 | TIGIT enhances CD4+ regulatory T-cell response and mediates immune suppression in a murine ovarian cancer model |
| Q53322899 | Targeted therapy in gynecologic cancers: Ready for prime time? |
| Q33750899 | The expression of Duffy antigen receptor for chemokines by epithelial ovarian cancer decreases growth potential |
| Q34354596 | The glycosphingolipid P₁ is an ovarian cancer-associated carbohydrate antigen involved in migration. |
| Q37396607 | The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins |
| Q38804092 | The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review |
| Q89587299 | Toll-Like Receptors Signaling in the Tumor Microenvironment |
| Q26861234 | Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies |
| Q90598483 | Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer |
| Q38904136 | Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells. |
| Q38958680 | Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells as Immunosuppressive Mechanism in Ovarian Cancer Patients: Progress and Challenges |
| Q35799695 | Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. |
| Q53235682 | [Nectins and nectin-like receptors DNAM-1 and CRTAM: new ways for tumor escape]. |
Search more.